Mode
Text Size
Log in / Sign up
Phase 4 Completed N=81 Supportive Care

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris

Source: ClinicalTrials.gov NCT01951417 ↗
Enrolled (actual)
81
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcomePrimary: Total Lesion Count — 76.7; 53.9; 50.0; 43.7 lesions

Summary

This is an open-label, multi-center study to be conducted in the United States. The study will examine the change in lesion count in subjects using Epiduo® Gel Pump (once daily) in conjunction with Cetaphil® DermaControl™ Foam Wash (twice daily) and Moisturizer SPF 30 (once daily). Subjects with a clinical diagnosis of mild or moderate acne who are eligible for treatment with Epiduo® in accordance with the currently approved product labeling and who meet other inclusion/exclusion criteria are to be enrolled in the study and receive the study products for 8 weeks. Efficacy and safety assessments include: complete lesion counts, cutaneous irritation assessment, end of study treatment questionnaire, photographic evaluation for oiliness, skin tone, and P Acnes, hydration assessment, barrier function assessment, treatment compliance, and adverse event assessment.

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Lesion Count
76.7; 53.9; 50.0; 43.7
SECONDARY
Inflammatory Lesions
27.3; 17.4; 15.7; 14.4
SECONDARY
Non-inflammatory Lesions
49.4; 36.4; 34.1; 29.2
SECONDARY
Subject Questionnaire
23; 42; 5; 3; 1; 3

Eligibility Criteria

Inclusion Criteria

  • Men and women of any race, 9 years or older, with a diagnosis of mild to moderate acne, who are eligible for treatment with adapalene BPO gel in accordance with the currently approved product labeling.

Exclusion Criteria

  • Subjects with nodules and cysts, pregnant or breastfeeding, with any systemic or dermatological disorder, or topical condition or facial hair that could interfere with evaluations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01951417). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search